Dolby Laboratories, Inc. Earnings Per Share Disclosure
| Fiscal Year Ended | |||||||||||
| September 26, 2025 | September 27, 2024 | September 29, 2023 | |||||||||
| Numerator: | |||||||||||
| Net income attributable to Dolby Laboratories, Inc. | $ | 255,018 | $ | 261,825 | $ | 200,656 | |||||
| Denominator: | |||||||||||
| Weighted-average shares outstanding—basic | 95,868 | 95,544 | 95,771 | ||||||||
| Potential common shares from options to purchase common stock | 358 | 586 | 763 | ||||||||
| Potential common shares from restricted stock units | 1,213 | 1,158 | 1,139 | ||||||||
| Potential common shares from employee stock purchase plan | 40 | 37 | 60 | ||||||||
| Weighted-average shares outstanding—diluted | 97,479 | 97,325 | 97,733 | ||||||||
| Net income per share attributable to Dolby Laboratories, Inc.: | |||||||||||
| Basic | $ | 2.66 | $ | 2.74 | $ | 2.10 | |||||
| Diluted | $ | 2.62 | $ | 2.69 | $ | 2.05 | |||||
| Antidilutive awards excluded from calculation: | |||||||||||
| Stock options | 1,448 | 1,152 | 930 | ||||||||
| Restricted stock units | 1 | 10 | 7 | ||||||||
| Employee stock purchase plan | 1 | 3 | 2 | ||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Nov 18, 2025 | Showing above |
| 2024 | Nov 19, 2024 | |
| 2023 | Nov 17, 2023 | |
| 2022 | Nov 18, 2022 | |
| 2021 | Nov 17, 2021 | |
| 2020 | Nov 16, 2020 | |
| 2019 | Nov 25, 2019 | |
| 2018 | Nov 15, 2018 | |
| 2017 | Nov 16, 2017 | |
| 2016 | Nov 18, 2016 | |
| 2015 | Nov 24, 2015 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.